Adults with aortic valve disorder do not experience reduction in survival rate

September 16, 2008

Young adults with a bicuspid aortic valve, a congenital heart abnormality, experience subsequent cardiac events but do not appear to have lower survival rates compared to the general population, according to a study in the September 17 issue of JAMA.

A bicuspid aortic valve in the heart is a valve that has only two flaps (cusps) that open and close, instead of three, and is the most common congenital cardiac abnormality in the adult population. Prior studies have reported significant death and illness in patients with bicuspid aortic valve related to the development of aortic valve dysfunction and inflammation of the heart valves, according to background information in the article. Cardiac outcomes in a contemporary population of adults with bicuspid aortic valve have not been determined.

Nikolaos Tzemos, M.D., of the University of Toronto, and Samuel C. Siu, M.D., S.M., of the University of Western Ontario, Canada, and colleagues examined the cardiac outcomes and disease progression in 642 adults, average age 35 years, with bicuspid aortic valve who were followed up for an average period of 9 years.

Independent predictors of primary cardiac events were age older than 30 years, moderate or severe aortic narrowing, and moderate or severe aortic regurgitation (flowing of blood back into the heart).

There was a total of 28 deaths (4 percent), of which 17 were cardiac-related (3 percent) and 11 were not related to a cardiac cause. The cardiac death rate was 0.3 percent per patient-year of follow-up. When compared with age- and sex-matched population estimates, the overall mortality was not significantly different between the bicuspid aortic valve group and in the population estimates. The 5-year average survival was 97 percent in both the bicuspid aortic valve group and in the population estimates. The 10-year survival was similar in both the bicuspid aortic valve group (96 percent) and in the population estimates (97 percent).

"Outcome differences between present and prior studies can be attributed to differences in the era that patients were examined, the population that was examined, the frequency of cardiac events associated with high mortality (aortic [tearing] and endocarditis [inflammation of the endocardium and heart valves]), and advances in perioperative management," the authors write.

Related Stories

A multicenter randomized trial evaluating the role of embolic protection using the Sentinel device during transcatheter aortic valve replacement (TAVR) found that the device was safe but did not meet the primary efficacy ...

(Medical Xpress)—A Painted Post woman is recovering after undergoing a less invasive heart-valve replacement procedure at the University of Rochester Medical Center. The valve replacement technique is meant for patients ...

TAVI is a safe alternative to redo cardiac surgery for failing bioprosthetic valves, according to research presented at the ESC Congress today by Dr. Spyridon Katsanos from the Netherlands. The findings suggest that transcatheter ...

New genetic research from an international team including McMaster University, University of Helsinki, Vilnius University and the University of Sydney, suggests that smallpox, a pathogen that caused millions of deaths worldwide, ...

Psoriasis is well-known for causing too many skin cells on elbows, knees, and across the body, but people living with psoriasis may also be at an increased risk of heart disease. Effects of overactive immune cells in the ...

In a new study, researchers have modified a rabies virus, so that it has a protein from the MERS virus; this altered virus works as a 2-for-1 vaccine that protects mice against both Middle East Respiratory Syndrome (MERS) ...